The few million in cash that this deal represents at present is just a small part of this deal. What is more important is the research and clinical development collaboration with a serious investor who does not appear to be interested in trading the stock as per BLT usual strategic investors. BLT has been branded as a complete joke by disgruntled investors and it's reputation has been smashed, unfairly, imo. But guess what? The richest and probably smarted dude in LA saw past all this B*S and decided it was worth a shot anyway. NantCapital have agreed to be funding source into the future on several development programs, not just the drug that has already shown proof-of-concept and may be in PII in the near future. This saves maybe five to ten years off a drug development program.
Sure, we don't have the fine detail yet, but, I don't know, but how many companies are out there right now trading below cash backing with this type of potential. Please, let me know if you find one, cause I sure can't.
The amount of absolute crap on the ASX trading 10 times higher than BLT with 1/100th of the potential is mindblowing.
BLT Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
